First FDA-Approved Corneal Cross-Linking Treatment for Keratoconus and Post-LASIK Ectasia is Now Available

Keratoconus and post-refractive surgery ectasia are corneal conditions that can have a significant impact on an individual’s day-to-day life. Thankfully, a new procedure recently approved by the U.S. Food and Drug Administration can effectively address these concerns without the need for surgical intervention, and our experienced eye surgeons are pleased to offer it here at The Eye Institute of Utah.

Our corneal specialists have been offering the Corneal Cross-Linking treatment through clinical trials for years, but with the recent FDA approval of this procedure (the first and only FDA-approved treatment of its kind available in the U.S.), it can now be performed for even more patients in Utah who may be candidates. Corneal cross-linking can help individuals who are affected by keratoconus, a progressive corneal disease that can cause significant visual distortion. While a corneal transplant has often been necessary to treat severe cases of keratoconus, corneal cross-linking now makes it possible to slow or stop the disease’s progression and prevent the need for surgery. In fact, many patients see an improvement in vision quality after this procedure and may even experience a reduction in the amount of vision correction necessary following treatment.

We are very excited to offer this long-awaited treatment option to our patients here at The Eye Institute of Utah. If you have questions, or if you would like to schedule a consultation, please contact us today.